Hopstem Biotechnology
PrivateLast Round
Series C
Aug 10, 2026
Total Funding Raised
$55.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Hopstem Biotechnology is a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived therapies for central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hopstem Biotechnology Comparables
Compare Hopstem Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XellSmart | 84% | |
| iRegene Therapeutics | 81% | |
| Allife Medicine | 80% |
Hopstem Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 10, 2026 | ||||
| Series B | Oct 31, 2021 | ||||
| Series A Extension | May 28, 2021 | ||||
| Series A Extension | Dec 1, 2020 | ||||
| Series A | Dec 24, 2018 |
Key People
Founding team and executive leadership
Hopstem Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cybernaut Investment Group | Angel |
| Longmen Capital | Series A Extension |
| Hillhouse Investment | Series B |
| YuanBio Venture Capital | Series B, Angel, Series A Extension |
| Daoyuan Capital | Series A |
| Tasly Capital | Series C |
| Empower Investment | Angel |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 414% MoM.
- Aug 10, 2026
Raised $28M with Tasly Capital participating.
Recent news
Latest coverage and updates
- receives_financingAug 10, 2026
Hopstem received financing of $29.7M in Series C on Aug 10th '26.
- recognized_asJun 20, 2026
Hopstem recognized as FDA RMAT designation for chronic stroke on Jun 3rd '26.
Hopstem Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hopstem Biotechnology's valuation, stock price, and market status.
Is Hopstem Biotechnology a public or private company?
Hopstem Biotechnology is a private company.
What is the current stock price of Hopstem Biotechnology?
Hopstem Biotechnology is a private company with no public stock price. No recent secondary market data is available.
How much is Hopstem Biotechnology worth (valuation)?
Valuation information for Hopstem Biotechnology is not publicly available.
Can I buy Hopstem Biotechnology stock?
Hopstem Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Hopstem Biotechnology's last funding round?
Hopstem Biotechnology's most recent funding round was Series B on October 31, 2021.
Who are the main investors in Hopstem Biotechnology?
Key investors in Hopstem Biotechnology include Hillhouse Investment, YuanBio Venture Capital, Daoyuan Capital.
Will Hopstem Biotechnology IPO soon?
No public IPO plans have been announced for Hopstem Biotechnology.
How can I track Hopstem Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Hopstem Biotechnology's secondary market activity and sign up for updates.